Gordion BIoscience

Executive Summary

Gordion Bioscience is a precision oncology company leveraging proprietary whole-genome sequencing of patient tumors and machine learning to identify novel, high-value drug targets. Founded in 2020 and headquartered in San Diego, the company integrates target discovery with patient stratification to streamline development of bispecific antibodies and other immunotherapies. By analyzing real patient tumor genomes, Gordion aims to address tumor heterogeneity and resistance mechanisms, potentially improving clinical outcomes. While still in the preclinical stage, the company's platform has the potential to generate a differentiated pipeline. Key risks include early-stage status, lack of disclosed in vivo validation, and competitive pressure from other AI-driven biotechs.

Upcoming Catalysts (preview)

• Q2 2026Presentation of preclinical data for lead bispecific antibody program at major oncology conference60% success
• Q4 2026IND filing for first-in-class target identified via Gordion's AI platform30% success
• Q3 2026Partnership or collaboration agreement with a larger pharma for co-development40% success